|
業務類別
|
Biotechnology |
|
業務概覽
|
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, isa subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD. |
| 公司地址
| 1210-1220 Washington Street, Suite 210, Newton, MA, USA, 02465 |
| 電話號碼
| +1 617 344-4190 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.acumenpharm.com |
| 員工數量
| 61 |
| Mr. Derek M. Meisner |
Chief Legal Officer |
-- |
23/04/2026 |
| Ms. Amy Schacterle |
Chief Regulatory Officer and Head of Quality |
-- |
23/04/2026 |
| Mr. William Matthew Zuga |
Principal Accounting Officer, Chief Financial Officer and Chief Business Officer |
美元 486.99K |
23/04/2026 |
| Dr. Jim Doherty, PhD |
President and Chief Development Officer |
美元 520.00K |
23/04/2026 |
| Mr. Daniel O'Connell |
Director and Chief Executive Officer |
美元 646.35K |
23/04/2026 |
| Dr. Eric Siemers, M.D. |
Chief Medical Officer |
-- |
23/04/2026 |
| Mr. Russell Barton, M.S. |
Chief Operating Officer |
-- |
23/04/2026 |
|
|
| Dr. Kimberlee Cobleigh Drapkin, PhD |
Independent Director |
23/04/2026 |
| Dr. George S. Golumbeski, PhD |
Chairman of the Board |
23/04/2026 |
| Dr. Jeffrey L. Ives, PhD |
Independent Director |
23/04/2026 |
| Mr. Sean Stalfort |
Independent Director |
23/04/2026 |
| Dr. Derrell D. Porter, M.D. |
Independent Director |
23/04/2026 |
| Mr. Daniel O'Connell |
Director and Chief Executive Officer |
23/04/2026 |
| Dr. Nathan B. Fountain, M.D. |
Independent Director |
23/04/2026 |
| Dr. Laura Stoppel, PhD |
Independent Director |
23/04/2026 |
|
|
|
|
